Kornimate/medical-research-clean huggingface dataset:
a study to evaluate the effect of the experimental glp-1 drug pf-07081532 on blood levels of common birth control pills, and drugs omeprazole and midazolam, and effect of glp-1 drug semaglutide on midazolam blood levels in healthy adults with weight in the obesity range

Conditions: Obesity

Summary: two different groups of healthy volunteers will be chronically treated with glp-1 drugs pf-07081532 or alternatively semaglutide. the effect of these glp-1 drugs on a single dose of the common sedative medication midazolam blood levels will be measured. the effect of chronic pf-07081532 on single doses of the common stomach acid medication omeprazole, and common birth control medication blood levels will also be measured. the hypothesis is that chronic administration of the glp-1 drugs will minimally affect blood levels from these common medications.


Eligibility criteria:
inclusion criteria: * healthy (no clinically relevant abnormalities) * bmi 30.0-45.4 inclusive exclusion criteria: * current or history of significant clinical condition * use of prescription or nonprescription drugs and dietary and herbal supplements within 7 or 14 days or 5 half-lives (whichever is longer) * pregnant * breast feeding

Keywords: midazolam omeprazole pf-07081532
the clinical study of the efficacy and safety of l-carnitine injection in treatment of heart failure

Conditions: Heart Failure,

Summary: the purpose of this study is to evaluate the efficacy and safety of l-carnitine injection in treatment of chinese patients with heart failure. a prospective, multicenter, randomized, double-blind, parallel, placebo-controlled clinical study was performed. treatment period: 7 days, follow-up: 1 month

the primary objective of this study is to assess the efficacy and safety of l-carnitine injection in treatment of chinese patients with heart failure.

Eligibility criteria:
inclusion criteria: 1. the subject aged ≥ 18 years, men or women. 2. the subject has a diagnosis of chronic left heart or right heart failure (a past medical history of left heart failure caused by coronary heart disease, hypertension and dilated cardiomyopathy, or a medical history of right heart failure caused by pulmonary artery hypertension (the 1st type of diagnostic classification, who conference, venice, 2003) and left heart disease (the 2nd type) ;the case number of right heart failure is about 30% of the total case number). 3. the subject needs hospitalization because of heart failure and will stay in hospital for more than 7 days. 4. nyha-fc is class ii- iv (class ii cases \< 20%, except the refractory terminal heart failure patients). 5. the subject's ucg shows that lvef ≤ 45％ (left heart failure). 6. ci \< 2.5 l/min/m2 or co \< 4l/min (right heart failure) 7. the subject has signed the icf. exclusion criteria: 1. subjects with medical history of heart failure caused by valvular heart disease, mechanical obstruction, pericardial disease and myocardial amyloidosis. 2. subjects with heart function class iv that have unstable hemodynamics and need final stage cardiac transplantation and intravenous vasoactive drugs. 3. subjects will leave the hospital in 7 days. 4. subjects with severe cerebral apoplexy (life threatening). 5. subjects with ami or acute pulmonary embolism. 6. subjects with uremia and did not undergo dialysis. 7. subjects with copd. 8. subjects with severe anemia (hb≤60g/l). 9. subject who is receiving other metabolism improving drugs within one month (such as trimetazidine dihydrochloride tablets and 1, 6- fructose diphosphate. 10. subject with other severe disease and his/her life expectancy \<12 months. 11. subject who has participated in other clinical trial within 3 months or is participating in other study. 12. subject who has received l-carnitine treatment within 1 month. 13. subject who is allergic to l-carnitine and its derivatives. 14. subject is receiving other cardiotoxic drugs. 15. subjects with medical history of epilepsy. 16. subject who is a drug or alcohol abuser. 17. subject who has received pci, cabg or vascular remodeling. 18. subject with arrhythmia that the investigator thinks unsuitable to include. 19. the subject who is pregnant or lactating, and the woman of childbearing age has not taken contraception measures. 20. the subject has not signed the icf.

Keywords: heart failure l-carnitine injection safety efficacy
the effect of two different endoscopic entry techniques on postoperative gastrointestinal function

Conditions: Gastrointestinal Disorder Postoperative

Summary: the purpose of this study is to determine effect of veres needle entry and direct trocar entry on postoperative gastrointestinal functions.

women planned to have laparoscopic surgery will be randomized into two groups, in first group pneumoperitoneum will be provided by veres needle, in other group direct trocar entry will be used to provide pneumoperitoneum. after surgery gastrointesitinal functions, shoulder pain, blood loss will be compared between groups.

Eligibility criteria:
inclusion criteria: * laparoscopic surgery for benign or malignant disease exclusion criteria: * patients with gastrointestinal intervention * patients who had undergone previous operations * patients with gastrointestinal intervention dysfunction
an observational study on efficacy and safety in subjects using levemir® for the treatment of insulin dependent type 1 or type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this observational study is conducted in africa. the aim of this observational study is to evaluate the efficacy and the incidence of serious adverse drug reactions while using insulin levemir® under normal clinical practice conditions.


Eligibility criteria:
inclusion criteria: * any subject with type 1 or type 2 diabetes mellitus is eligible for the study, including newly-diagnosed subjects who have never received insulin or an insulin analogue before. the selection of the subjects will be at the discretion of the individual physician exclusion criteria: * subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit * currently being treated with insulin detemir * previously enrolled in this study * hypersensitivity to insulin detemir or to any of the excipients * pregnancy, breast-feeding, the intention to become pregnant or judged not to be using adequate contraceptive measures.
impact of a mailed educational reminder on fecal occult blood testing (fobt): a randomized controlled trial

Conditions: Colon Cancer

Summary: the purpose of our randomized controlled trial is to determine whether mailed educational reminders would increase fecal occult blood test (fobt) card return rates and, therefore, improve patient compliance with colonrectal cancer (crc) screening. we will conduct a randomized, controlled trial to evaluate the hypothesis that compliance to fobt referrals is at least 10% greater among patients who receive mailed educational reminders on the importance of crc screening. the study will be conducted in veteran affairs medical center and surrounding va clinics in san diego.

colorectal cancer (crc) is the third most common cancer in men and women in the united states with an estimated 147,000 new cases and more than 56,000 deaths each year. early detection of colon cancer and removal of precancerous adenomatous polyps have been shown to reduce its morbidity, mortality and incidence. there are several recommended crc screening tests, including fecal occult blood test (fobt), flexible sigmoidoscopy, air-contrast barium enema, and colonoscopy. in the va, fobt is the predominant screening test for crc, however patient compliance is low. numerous studies have evaluated patient participation in crc screening programs and fobt card return rates, all of which have shown patient adherence was suboptimal. to date, there are no studies that have evaluated whether mailed educational reminders can improve fobt compliance. the purpose of our randomized controlled trial is to determine whether mailed educational reminders would increase fobt card return rates and, therefore, improve patient compliance with crc screening.

Eligibility criteria:
inclusion criteria: * asymptomatic men and women age 50 years or older who received screening fobt card kits from the laboratory exclusion criteria: * are less than 50 years of age * are inpatients * are not undergoing routine colon cancer screening

Keywords: colon cancer screening mail reminders fecal occult blood test compliance
cognitive & motor training after stroke for everyday walking restoration

Conditions: Stroke

Summary: the purpose of this study is to test a unique, combined cognitive and motor intervention designed to restore safe, more normal coordinated gait components into the real world environment for individuals with stroke.


Eligibility criteria:
inclusion criteria: * greater than or equal to 6 months post stroke * ability to give informed consent * impaired gait * medically stable exclusion criteria: * pacemaker * unstable/uncontrolled medical condition(s)

Keywords: stroke gait training cognitive training
impact of cardiac magnetic resonance imaging on endothelial function in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: magnetic resonance (mr) imaging is a widely used and well-established noninvasive medical diagnostic imaging tool. by using a static and a gradient magnetic field in combination with a radiofrequency field (rf), mr provides excellent contrast among different tissues of the body. although long-term effects on human health from exposure to strong static magnetic fields seem unlikely, acute effects such as vertigo, nausea, change in blood pressure, reversible arrhythmia, and neurobehavioural effects have been documented from occupational exposition to 1.5 t. cardiac mr (cmr) imaging requires some of the strongest and fastest switching electromagnetic gradients available in mr exposing the patients to the highest administered energy levels accepted by the controlling authorities. studies focusing on experimental teratogenic or carcinogenic effects of mr revealed conflicting results. since cmr is emerging as one of the fastest growing new fields of broad mr application, it is of particular concern that a recent in vitro study with cmr sequences has reported on cmr-induced dna damages in white blood cells up to 24 h after exposure to 1.5 t cmr. therefore, we hypothesized that cmr can induce the damage of endothelium and endothelial progenitor cells in type 2 diabetes


Eligibility criteria:
inclusion criteria: * male * age 30 to 65 years old * type 2 diabetes exclusion criteria: * renal and liver function dysfunction * heart failure * malignancy * patients with contraindications to cardiac magnetic resonance (cmr) * patients with clinical detectable angiopathy
lung cancer screening protocol

Conditions: Lung Cancer Screening

Summary: the successful implementation of lung cancer screening across diverse setting requires working with the community and primary care practices. collaborating across diverse community-based sites will employ local knowledge and culture in the understanding of the health problem and identifying and implementing solutions that are appropriate for all partners (patients, primary care, referral centers). enhanced, culturally-competent communication with patients at high risk for lung cancer can narrow inequities in screening awareness, referral, and utilization, as well as improve lung cancer outcomes across diverse patients and communities. promoting partnerships among physicians, staff, and patients; creating routines; and tailoring materials to each clinician's situation have been show to increase the proportion of patients receiving screening.


Eligibility criteria:
inclusion criteria: * to be eligible to participate in the trial, screening centers have to be existing members of the bjc collaborative. * primary care providers have to have a referral relationship with the screening center; serve adult patients who may be screening-eligible, and are willing to interact with the referral site to implement referral for ldct. exclusion criteria: there are not any exclusion criteria for the study
description of the use of subcutaneous acetaminophen in palliative care unit in france: descriptive questionnaire survey

Conditions: Pain

Summary: acetaminophen is a drug commonly used in palliative care unit, for its antalgic and antipyretic effects. several administration routes are possible but the use of the sub-cutaneous route is actually not supported by recommandations.


Eligibility criteria:
inclusion criteria: * doctors responsible for palliative care unit in france exclusion criteria: -

Keywords: palliative care; acetaminophen; subcutaneous route; pain treatment
comparison between volume controlled ventilation and pressure controlled ventilation

Conditions: Obesity; Reduced Lung Compliance.; Anesthesia.; Laparoscopy.

Summary: to assess the potential benefits on mechanical ventilation plateau pressure of pressure controlled mode versus volume controlled mode for laparoscopic bariatric surgery in obese patients (bmi \> 35). high plateau pressures encountered in obese patients due to their reduced pulmonary compliance could be lowered using pressure controlled mechanical ventilation.

all patients are over 18 years old and give their inform consent after approval of the study protocol by an ethic committee. anesthesia is standardized and all patients are intubated. precise protocols are used to perform pressure and volume controlled ventilation in order to regulate end-tidal co2 between 33 and 35 mmhg. primary goal is comparison of plateau pressures observed in the 2 ventilation modes after 45 minutes of pneumoperitoneum. secondary goals are : comparison of pao2 and paco2 after 45 minutes of pneumoperitoneum and after 2 hours spent in post-anesthesia care unit ; comparison of total respiratory resistances and peak flow generated between the 2 modes.

Eligibility criteria:
inclusion criteria: * patients are over 18 years old and give their inform consent * morbid obesity(bmi\>35) * laparoscopic bariatric surgery exclusion criteria: -

Keywords: obesity. respiration. respiration, artificial. ventilation. pressure controlled. volume controlled.
a research study looking at how oral semaglutide works in people with type 2 diabetes in sweden, as part of local clinical practice

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how rybelsus® works in people with type 2 diabetes and to see if rybelsus® can lower their blood sugar levels. participants will get rybelsus® as prescribed to them by the study doctor. the study will last for about 8-10 months. participants will be asked to complete a questionnaire about how they take their rybelsus® tablets. participants will complete this questionnaire during their normally scheduled visit with the study doctor. participants will be asked to complete some questionnaires about their diabetes treatment. participants will complete these during normally scheduled visits with the study doctor.


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * diagnosed with type 2 diabetes mellitus * the decision to initiate treatment with commercially available oral semaglutide has been made by the patient/legally acceptable representative (lar) and the treating physician based on local label before and independently from the decision to include the patient in this study * male or female, age above or equal to 18 years at the time of signing informed consent * available hba1c value less than or equal to 90 days prior to the 'informed consent and treatment initiation visit' (v1) or hba1c measurement taken in relation with the 'informed consent and treatment initiation visit'(v1) if in line with local clinical practice * treatment naïve to injectable glucose-lowering drug(s). an exception is short-term insulin treatment for acute illness for a total of less than or equal to 14 days exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study * treatment with any investigational drug within 30 days prior to enrolment into the study * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
a trial of shr-a1912 combined with other therapies in b-cell non-hodgkin 's lymphoma

Conditions: B-cell Non-Hodgkin's Lymphoma

Summary: this study aims to evaluate the safety, pk and preliminary anti-tumour activity of shr-a1912 combined with other therapies in patients with b-cell non-hodgkin 's lymphoma.


Eligibility criteria:
inclusion criteria: 1. age greater than or equal to18 years old; 2. eastern cooperative oncology group (ecog) performance status is 0 to 1; 3. life expectancy \>3 months; 4. histologically confirmed b-cell b-cell non-hodgkin's lymphoma; 5. previous systematic anti-tumor therapy should meet the following requirements: 1) relapsed and/or refractory disease after at least one (≥ 1) line of prior systemic therapy (relapsed/refractory cohort); 2) previously untreated (naïve cohort). 6. at least one measurable nodal lesion, defined as \> 1.5 cm in its longest dimension, or one measurable extra nodal lesion, defined as \> 1.0 cm in its longest diameter. exclusion criteria: 1. received autologous stem cell transplantation within 12 weeks before the first study treatment; previously received allogeneic stem cell transplantation; received car-t cell therapy within 12 weeks before the first study treatment; 2. history of recent major surgery or severe trauma within 4 weeks before the first study treatment; 3. received anti-tumour treatment within 2 weeks before the first study treatment; 4. central nervous system (cns) infiltration; 5. active infection with hbv or hcv; 6. history of immunodeficiency, including hiv serotest positive, or other acquired or congenital immunodeficiency diseases, and active tuberculosis; 7. active infection or unexplained fever\>38.5℃; 8. history of severe cardiovascular disease.
clinical study of novel diagnostic techniques for knee osteoarthritis

Conditions: Knee Osteoarthritis; Knee Injuries

Summary: the purpose of this study is to clarify the potential of intra-articular ultrasound imaging, non-invasive ultrasound imaging, quantitative mri imaging, contrast-enhanced ct imaging and arthroscopy for diagnostics of knee osteoarthritis. all methods will be cross-correlated and compared with the arthroscopic findings.


Eligibility criteria:
inclusion criteria: * kellgren-lawrence grade = 1-3 or cartilage defect detected in mri * age \>= 20 years exclusion criteria: * tumor or inflammation in the knee * severe general diseases * diabetes
clinical curative effect evaluation study of treatment of oral deferiprone tablets in aceruloplasminaemia patients

Conditions: Aceruloplasminemia

Summary: aceruloplasminemia is an autosomal recessive disorder characterized by iron deposition in the brain and visceral organs. deferiprone was used to treat aceruloplasminemia in previous study. in this study, we will assess the clinical curative effect evaluation of oral deferiprone in chinese aceruloplasminemia patients.

diabetes is one of the most severe symptom in aceruloplasminemia. in this study, we use r2\* of pancreas mri to evaluate the effect of deferiprone treatment.

Eligibility criteria:
inclusion criteria: * age 18-80 years * diagnosed with aceruloplasminaemia * genetically confirmed diagnosis of aceruloplasminaemia exclusion criteria: * contraindications to deferiprone therapy * pregnancy was excluded in women of childbearing age

Keywords: aceruloplasminemia deferiprone pancreas mri
combined behavioral and analgesic trial for fibromyalgia

Conditions: Fibromyalgia

Summary: this is a randomized control study that involves a combination of a drug treatment, behavioral health, and placebo controls. some participants will receive a medication approved by the food and drug administration for treatment of moderate to moderately severe pain called tramadol hc1 ir. others will receive an inactive pill, called a placebo. there will also be 2 different types of behavioral health treatments, cognitive-behavior therapy (cbt) and health education (he) both of which have been recommended for the treatment of patients with fm by the american pain society. there are 4 possible study treatment combinations: 1. tramadol + cbt, 2. tramadol + he, 3. placebo + cbt, 4. placebo + he. although tramadol, cbt, and he have been shown to have some benefits for fm patients, there have been no studies that have evaluated the combination of medication and a behavioral health treatment. the primary purpose of this study is to compare the benefits of the 4 combinations listed.


Eligibility criteria:
inclusion criteria: * males and females 21-70 * diagnosis of fibromyalgia * current primary care physician * fluent in english exclusion criteria: * rheumatologic disorders * drug and alcohol abuse in the past year * psychiatric hospitalization in the past 6 months * current use of tramadol * certain antidepressant and other pain medications
tralokinumab in combination with topical corticosteroids in japanese subjects with moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: primary objective: to evaluate the efficacy of tralokinumab in combination with topical corticosteroids (tcs) compared with placebo in combination with tcs in treating moderate-to-severe atopic dermatitis (ad). secondary objectives: to evaluate the efficacy of tralokinumab in combination with tcs on severity and extent of ad, itch, health-related quality of life, and health care resource utilisation compared with placebo in combination with tcs. to assess the safety of tralokinumab in combination with tcs when used to treat moderate-to-severe ad for 16 weeks.


Eligibility criteria:
key inclusion criteria: * japanese subject aged 18 years and above. * diagnosis of ad as defined by the hanifin and rajka (1980) criteria for ad. * history of ad for 1 year or more. * a recent history (within 1 year before screening) of inadequate response to treatment with topical medication. * ad involvement of 10% or more body surface area at screening and at baseline according to component a of scorad. * applied a stable dose of emollient twice daily (or more, as needed) for at least 14 days before randomisation. key exclusion criteria: * subjects for whom tcs are medically inadvisable e.g. due to important side effects or safety risks in the opinion of the investigator. * active dermatologic conditions that may confound the diagnosis of ad or would interfere with assessment of treatment. * use of tanning beds or phototherapy within 6 weeks prior to randomisation. * treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroids within 4 weeks prior to randomisation. * treatment with tcs, topical calcineurin inhibitors, topical phosphodiesterase-4 inhibitors, or topical janus kinase inhibitors within 2 weeks prior to randomisation. * receipt of any marketed biological therapy (i.e. immunoglobulin, anti-immunoglobulin e) including dupilumab or investigational biologic agents 3 to 6 months prior to randomisation. * active skin infections within 1 week prior to randomisation. * clinically significant infection within 4 weeks prior to randomisation. * a helminth parasitic infection within 6 months prior to the date informed consent is obtained. * tuberculosis requiring treatment within the 12 months prior to screening. * known primary immunodeficiency disorder.